Procyon Technologies LLC and Novo Nordisk A/S to Collaborate on the Development of a Stem-Cell Based Therapy for Type 1 Diabetes | More News
Hits: 845 TUCSON, AZ, USA I December 8, 2020 I Procyon Technologies LLC today announced that it has entered into an exclusive research collaboration and license agreement with Novo Nordisk A/S to develop an implantable cell encapsulation device to be used in Novo Nordisks development of a novel therapy for Type 1 diabetes. The collaboration brings together Procyon Technologies expertise with development of oxygen enabled implantable cell encapsulation devices and Novo Nordisks expertise in ...
Source: pipelinereview.com